Triple Threat: Triple Pathogen Endocarditis.
Gonzalez JM, Lowenhaar G, Ramgopal M, Chalasani P.
Cureus. 2023 Oct 28;15(10):e47860. doi: 10.7759/cureus.47860. eCollection 2023 Oct.
Chronic hepatitis C genotype 1 virus: who should wait for treatment?
Tovo CV, de Mattos AA, de Almeida PR.
World J Gastroenterol. 2014 Mar 21;20(11):2867-75. doi: 10.3748/wjg.v20.i11.2867.
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E, Piluso A, Caini P, Ranieri J, Monti M, Laffi G, Zignego AL.
Dig Liver Dis. 2014 Sep;46(9):833-7. doi: 10.1016/j.dld.2014.05.017. Epub 2014 Jun 19.
Management of side-effects.
Rosa I.
Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S69-74. doi: 10.1016/S2210-7401(11)70011-0.
Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.
Teixeira R, Nascimento Yde A, Crespo D.
Braz J Infect Dis. 2013 Mar-Apr;17(2):194-204. doi: 10.1016/j.bjid.2012.10.010. Epub 2013 Mar 9.
Management of HCV patients with cirrhosis with direct acting antivirals.
Boccaccio V, Bruno S.
Liver Int. 2014 Feb;34 Suppl 1:38-45. doi: 10.1111/liv.12391.
Telaprevir: changing the standard of care of chronic hepatitis C.
Rajani AK, Ravindra BK, Dkhar SA.
J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493.
The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection.
Freekh DA, Helmy MW, Said M, El-Khodary NM.
Saudi Pharm J. 2021 Oct;29(10):1120-1128. doi: 10.1016/j.jsps.2021.08.006. Epub 2021 Aug 4.
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA.
Aliment Pharmacol Ther. 2014 May;39(10):1213-24. doi: 10.1111/apt.12718. Epub 2014 Mar 24.
[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].
Vince A, Duvnjak M, Kurelac I.
Acta Med Croatica. 2013 Oct;67(4):329-38.
